Plus   Neg

Regeneron Pharma Reports Positive Phase 3 Results For Evinacumab - Quick Facts

Regeneron Pharmaceuticals, Inc. (REGN) said a Phase 3 study of evinacumab in patients with homozygous familial hypercholesterolemia met its primary endpoint. In the trial, the investigational angiopoietin-like 3 antibody, when added to other lipid-lowering therapies, decreased LDL cholesterol by 49% on average, compared to lipid-lowering therapies alone. In the study, evinacumab was well-tolerated.

The company said the detailed results from the trial will be presented at a future medical meeting. Data will be submitted to regulatory authorities, with the FDA in 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT